Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins
Journal of the American Chemical Society · 17.05.2023 · 145 (19) · 10872-10879
DOI: 10.1021/jacs.3c02783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 04.05.2023. Verfasst von Zhen Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, United States. Hauptthemen laut MEDLINE: Telomeric Repeat Binding Protein 1, Telomere. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Telomeres are naturally shortened after each round of cell division in noncancerous normal cells, while the activation of telomerase activity to extend telomere in the cancer cell is essential for cell transformation. Therefore, telomeres are regarded as a potential anticancer target. In this study, we report the development of a nucleotide-based proteolysis-targeting chimera (PROTAC) designed to degrade TRF1/2 (telomeric repeat-binding factor 1/2), which are the key components of the shelterin complex (telosome) that regulates the telomere length by directly interacting with telomere DNA repeats. The prototype telomere-targeting chimeras (TeloTACs) efficiently degrade TRF1/2 in a VHL- and proteosome-dependent manner, resulting in the shortening of telomeres and suppressed cancer cell proliferation. Compared to the traditional receptor-based off-target therapy, TeloTACs have potential application in a broad spectrum of cancer cell lines due to their ability to selectively kill cancer cells that overexpress TRF1/2. In summary, TeloTACs provide a nucleotide-based degradation approach for shortening the telomere and inhibiting tumor cell growth, representing a promising avenue for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, United States.
- Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, U…
- Department of Biochemistry & Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
- Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
ORCID-Profile: H Ümit Kaniskan, Jian Jin, Wenyi Wei
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
Zitieren
APA
Wang, Z., Liu, J., Chen, H., Qiu, X., Xie, L., Kaniskan, H. Ü., Chen, X., Jin, J., & Wei, W. (2023). Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins. Journal of the American Chemical Society, 145(19), 10872-10879. https://doi.org/10.1021/jacs.3c02783
Vancouver
Wang Z, Liu J, Chen H, Qiu X, Xie L, Kaniskan HÜ, et al. Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins. Journal of the American Chemical Society. 2023;145(19):10872-10879. doi:10.1021/jacs.3c02783
BibTeX
@article{Wang2023,
author = {Wang, Zhen and Liu, Jing and Chen, He and Qiu, Xing and Xie, Ling and Kaniskan, H Ümit and Chen, Xian and Jin, Jian and Wei, Wenyi},
title = {Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins},
journal = {Journal of the American Chemical Society},
year = {2023},
volume = {145},
number = {19},
pages = {10872--10879},
doi = {10.1021/jacs.3c02783}
}
EUVIMED